Findings published in PLoS One indicated that the solubility of trans-resveratrol could be enhanced using ribose and that absorption of resveratrol is possible via the mucous membrane in the mouth.
“The oral transmucosal delivery method appears to elevate peak plasma level of trans-resveratrol above that previously reported following GI absorption (e.g., powder, caplets) in humans,” wrote the researchers.
“Given the limited number of excipients tested, limited dosage forms, and the small number of human participants this should be considered a proof of concept study which provides the first evidence to support further pursuit towards development of a resveratrol lozenge optimized for human oral transmucosal absorption.”
The study was funded by Wilmore Labs, LLC from San Antonio, TX, a start-up company which aims to develop novel formulations for nutraceutical delivery, and the company’s president and CTO, Otis Blanchard, is first author of the paper. The study was performed in collaboration with researchers from the University of Texas Health Science Center at San Antonio, High Point University in North Carolina.
The resveratrol-ribose lozenge is the subject of a pending patent application (2011/0130,469) by Blanchard, who told NutraIngredients-USA that he has been working on the resveratrol lozenge for four years, and the company is actively engaged in pursing commercialization of the product. The bottleneck for further development is investment, he said, and the company is exploring various options to move forward, including crowd-funding.